USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
OPHIDION, INC.
Address:
2265 E. Foothill Blvd
Pasadena, CA 91107-0000
Phone:
N/A
URL:
N/A
EIN:
126188525
DUNS:
825379659
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,156,365.00 2
STTR Phase I $296,028.00 1

Award List:

Improved Cell Line and Assay Development of Nicotinic Receptor Complexes for HTS

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Nicotine consumption is linked to improvements in cognitive functions such as attention and memory, as well as improvements in symptoms for those suffering from disorders such as anxiety, depression and schizophrenia. F urthermore, nicotinic receptors in the… More

Biologic approach to targeting a nicotinic receptor accessory molecule for cognit

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$656,365.00
Agency:
HHS
Principal Investigator:
Andreas Walz – 646-326-9717
Abstract:
DESCRIPTION (provided by applicant): The proposed project details a biologic strategy for the therapeutic targeting of nicotinic receptors of the cholinergic system for the treatment of mental and neurological disorders. The cholinergic system is an important modulatory neurotransmitter system,… More

In vivo and in vitro tools to target CHRNA5 for smoking cessation.

Award Year / Program / Phase:
2011 / STTR / Phase I
Award Amount:
$296,028.00
Agency:
HHS
Principal Investigator:
Andreas Walz – 646-326-9717
Research Institution:
CALIFORNIA INSITUTE OF TECHNOLOGY
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Nicotine is one of the most heavily used addictive drugs and accounts for 90% of lung cancer cases in the U.S. Recent studies have implicated a specialized receptor class binding to nicotine, the CHRNA5 gene, which encodes the a5 subunit of the nicotinic… More